arrow
L

Lisa H. Butterfield

Parker Institute for Cancer Immunotherapy
H指数:67
被引数:1.6万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Associations between immune checkpoint inhibitor response, immune-related adverse events, and steroid use in RADIOHEAD: a prospective pan-tumor cohort study

免疫检查点抑制剂反应、免疫相关不良事件和糖皮质激素使用之间的关系:RADIOHEAD一项前瞻性泛肿瘤队列研究

2025-05-120
OA
Immunologic signatures of response and resistance to nivolumab with ipilimumab in advanced metastatic cancer
2024-08-270
OAAI
EXPLORATORY PLATFORM TRIAL TO EVALUATE IMMUNOTHERAPY COMBINATIONS WITH CHEMOTHERAPY FOR THE TREATMENT OF PATIENTS WITH PREVIOUSLY UNTREATED METASTATIC PANCREATIC ADENOCARCINOMA (REVOLUTION)
2022-11-070
OA
Co-expression of TNF receptors 1 and 2 on melanomas facilitates soluble TNF-induced resistance to MAPK pathway inhibitors

肿瘤坏死因子受体1和2在黑色素瘤上的共表达促进可溶性肿瘤坏死因子诱导的对MAPK通路抑制剂的抗性

2022-07-255
OAAI
Mass cytometry detects H3.3K27M-specific vaccine responses in diffuse midline glioma (vol 130, pg 6325, 2020)
2022-06-155
OA
Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial

Sotigalimab和/或nivolumab联合化疗一线转移性胰腺癌: 来自PRINCE随机2期试验的临床和免疫学分析

2022-06-03170
OAAI
Enhanced immune activation within the tumor microenvironment and circulation of female high-risk melanoma patients and improved survival with adjuvant CTLA4 blockade compared to males
2022-06-036
OAAI
Improved prognosis and evidence of enhanced immunogenicity in tumor and circulation of high-risk melanoma patients with unknown primary

原发性未知的高危黑色素瘤患者的预后改善和肿瘤和循环中免疫原性增强的证据

2022-01-248
OAAI